Background Erosive osteoarthritis (EOA) is a form of severe involvement of osteoarthrosis in the hands, characterized by inflammation of the synovium of the proximal interphalangeal (PIF) and distal joints (DIF); the last ones are the most affected in a symmetrical manner. Inhibition of interleukin 6 (IL-6) in joints with osteoarthrosis helps to improve the production of the cartilaginous matrix and microfractures of articular cartilage.
Objectives To know if the application of TCZ is useful for the control of the clinical manifestations of EOA of the hands.
Methods Twenty-four patients with EOA were studied, 18 females and 6 males with ages ranging from 42 to 72 years, with an evolution time of 4 to 30 years. The application of TCZ was intravenous (8 mg/kg of body weight per month).
Articular pain in the PIF and distal joints was evaluated by the visual analogue scale (VAS) (0 to 10) and joint pain (0 to 50), morning stiffness (0 to 10), and functional limitation (0–90) by the AUSCAN index.
Results The VAS showed improvement of 30% (0% to 100%). The AUSCAN index showed improved pain (16.2), morning stiffness (0.6) and functional limitation (17.5). Decreased ESR, CRP, and IL-6 levels less than 1.56 to 59.1 pg/ml.
Conclusions IV Tocilizumab is useful for the control of the clinical manifestations of OAE of the hands. More precise studies are needed to evaluate the improvement of the cartilaginous matrix in EOA by TCZ.
Disclosure of Interest None declared